Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc. (PMCB) on October 7, 2022, covering events occurring on October 6, 2022. The filing addresses significant executive leadership changes, specifically the resignation of the Chief Executive Officer and President, and the appointment of interim leadership.
Key Financial Metrics
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the executive separation agreement:
- Lump Sum Payment: $216,667 payable to the departing CEO within five business days of the agreement's effective date (October 13, 2022).
- Consulting Fees: $433,333 total, payable in twelve monthly installments over a one-year consulting period.
- Other Compensation: Payment of earned but unpaid salary and reimbursement of reasonable business expenses incurred prior to the separation date.
Material Changes
The primary material change is the departure of Kenneth L. Waggoner, who resigned as CEO, President, General Counsel, and Director effective October 6, 2022. Concurrently, the Board appointed Joshua N. Silverman, a director since August 2022, as Interim Chairman, Interim CEO, and Interim President. Mr. Silverman's tenure is expected to be for an indeterminate amount of time.
Outlook, Risks, and Contingencies
Management commentary is limited to the transition of duties. Mr. Waggoner has agreed to serve as a consultant for twelve months to facilitate the orderly transfer of work. The Separation Agreement includes mutual releases of claims and non-disparagement obligations. Mr. Waggoner remains subject to restrictive covenants, including non-compete and non-solicit agreements. The filing notes that a compensatory agreement for Mr. Silverman is expected to be entered into in the near future.
Investor Verification Checklist
- Verify the exact terms of the compensatory agreement for Interim CEO Joshua N. Silverman once filed.
- Review the full Separation, Consulting and Release Agreement (Exhibit 10.1) for details on restrictive covenants and expense reimbursements.
- Monitor subsequent filings for the appointment of a permanent CEO and any impact on the company's strategic direction.
- Confirm the status of the 15,000 stock options and 23,000 restricted stock units retained by Mr. Waggoner.